Statistics for Efficacy safety and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr81 trial
Total visits
| views | |
|---|---|
| Efficacy safety and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr81 trial | 3 |
Total visits per month
| views | |
|---|---|
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 3 |
| April 2025 | 0 |
| May 2025 | 0 |
File Visits
| views | |
|---|---|
| Journal Article.pdf | 5 |